SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295306.
  • 2
    Derksen RH, de Groot PG. The obstetric antiphospholipid syndrome. J Reprod Immunol 2008; 77: 4150.
  • 3
    Tincani A, Bazzani C, Zingarelli S, Lojacono A. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost 2008; 34: 26773.
  • 4
    Ruffatti A, Calligaro A, Hoxha A, Trevisanuto D, Ruffatti AT, Gervasi MT, et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) 2010; 62: 3027.
  • 5
    Ruffatti A, Tonello M, Visentin MS, Bontadi A, Hoxha A, De Carolis S, et al. Risk factors for pregnancy failure in patients with anti-phospholipd syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 2011; 50: 16849.
  • 6
    Branch DW. Antiphospholipid antibodies and fetal compromise. Thromb Res 2004; 114: 4158.
  • 7
    Meroni PL, di Simone N, Testoni C, D'Asta M, Acaia B, Caruso A. Antiphospholipid antibodies as cause of pregnancy loss. Lupus 2004; 13: 64952.
  • 8
    Stephenson MD. Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril 1996; 66: 249.
  • 9
    Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 2537.
  • 10
    Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 15849.
  • 11
    Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996; 87: 48993.
  • 12
    Ruffatti A, Tonello M, Del Ross T, Cavazzana A, Grava C, Noventa F, et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006; 96: 33741.
  • 13
    Do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet Gynecol 2010; 116: 143343.
  • 14
    Al-Mishari AA, Gader AG, Al-Jabbari AW, Al-Momen AK, El Rab MO, Babay ZH, et al. The prevalence of lupus anticoagulant in normal pregnancy and in women with recurrent fetal loss: recommendations for laboratory testing for lupus anticoagulant. Ann Saudi Med 2004; 24: 42933.
  • 15
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 16
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 17
    ACOG Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin: diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002; 99: 15967.
  • 18
    Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996; 87: 1638.
  • 19
    American College of Obstetritions and Gynecologists. Intrauterine growth restriction. ACOG practice bulletin 12, reaffirmed 2010. Washington: ACOG; 2000.
  • 20
    ACOG Committee on Practice Bulletins. ACOG practice bulletin: ultrasonography in pregnancy. Obstet Gynecol 2004; 104: 144958.
  • 21
    Clark-Soloninka CA, Spitzer KA, Nadler J, Laskin CA. Evaluation of screening 590 plasma samples for the lupus anticoagulant using a panel of four tests [abstract]. Arthritis Rheum 1998; 41 Suppl: S168.
  • 22
    Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al, and the Subcommittee on Lupus Anticoagulant /Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7: 173740.
  • 23
    Qamar T, Levy RA, Sammaritano L, Gharavi AE, Lockshin MD. Characteristics of high-titer IgG antiphospholipid antibody in systemic lupus erythematosus patients with and without fetal death. Arthritis Rheum 1990; 33: 5014.
  • 24
    Harris EN, and the Kingston Anti -Phospholipid Antibody Study (KAPS) Group. The second international anti-cardiolipin standardization workshop. Am J Clin Pathol 1990; 94: 476484.
  • 25
    Erkan D, Zhang HW, Shriky RC, Merrill JT. Dual antibody reactivity to β2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome. Lupus 2002; 11: 21520.
  • 26
    Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159: 7026.
  • 27
    Soulier J, Boffa M. Avortements à repetition, thromboses et anticoagulant circulant antithromboplastine. Nouv Presse Med 1980; 9: 859864.
  • 28
    Ganzevoort W, Rep A, De Vries JI, Bonsel GJ, Wolf H. Relationship between thrombophilic disorders and type of severe early-onset hypertensive disorder of pregnancy. Hypertens Pregnancy 2007; 26: 43345.
  • 29
    Alijotas-Reig J, Ferrer-Oliveras R, Rodrigo-Anoro MJ, Farran-Codina I, Cabero-Roura L, Vilardell-Tarres M. Anti-β(2)-glycoprotein-I and anti-phosphatidylserine antibodies in women with spontaneous pregnancy loss. Fertil Steril 2010; 93: 23306.
  • 30
    Agostinis C, Biffi S, Garrova C, Durigutto P, Lorenzon A, Bek A, et al. In vivo distribution of (β)2 glycoprotein I under various pathophysiologic conditions. Blood 2011; 118: 42318.
  • 31
    Dembitzer FR, Ledford Kraemer MR, Meijer P, Peerschke EI. Lupus anticoagulant testing: performance and practices by North American clinical laboratories. Am J Clin Pathol 2010; 134: 76473.
  • 32
    Moffat KA, Ledford-Kraemer MR, Plumhoff EA, McKay H, Nichols WL, Meijer P, et al. Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practices. Thromb Haemost 2009; 101: 17884.
  • 33
    Triplett DA. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls. J Autoimmun 2000; 15: 1738.
  • 34
    Tripodi A. Laboratory testing for lupus anticoagulants: a review of issues affecting results. Clin Chem 2007; 53: 162935.
  • 35
    Erkan D, Derksen WJ, Kaplan V, Sammaritano L, Pierangeli SS, Roubey R, et al. Real world experience with antiphospholipid antibody tests: how stable are results over time? Ann Rheum Dis 2005; 64: 13215.
  • 36
    Erkan D, Barbhaiya M, George D, Sammaritano L, Lockshin M. Moderate versus high-titer persistently anticardiolipin antibody positive patients: are they clinically different and does high-titer anti-β 2-glycoprotein-I antibody positivity offer additional predictive information? Lupus 2010; 19: 6139.
  • 37
    Lassere M, Empson M. Treatment of antiphospholipid syndrome in pregnancy: a systematic review of randomized therapeutic trials. Thromb Res 2004; 114: 41926.